Portal de Periódicos da CAPES

Haemodynamic effects of H 2 ‐receptor antagonists

1992; Wiley; Volume: 22; Issue: 1 Linguagem: Inglês

10.1111/j.1365-2362.1992.tb01929.x

1365-2362

Holger Hinrichsen, Atef Halabi, Wilhelm Kirch,

Gastroesophageal reflux and treatments

European Journal of Clinical InvestigationVolume 22, Issue 1 p. 9-18 Haemodynamic effects of H2-receptor antagonists H. HINRICHSEN, H. HINRICHSEN 1st Medical Clinic, Christian Albrechts University, Kiel, GermanySearch for more papers by this authorA. HALABI, A. HALABI 1st Medical Clinic, Christian Albrechts University, Kiel, GermanySearch for more papers by this authorW. KIRCH, Corresponding Author W. KIRCH 1st Medical Clinic, Christian Albrechts University, Kiel, GermanyI. Medizinische Klinik, SchittenhelmstraBe 12, D-2300 Kiel, Germany.Search for more papers by this author H. HINRICHSEN, H. HINRICHSEN 1st Medical Clinic, Christian Albrechts University, Kiel, GermanySearch for more papers by this authorA. HALABI, A. HALABI 1st Medical Clinic, Christian Albrechts University, Kiel, GermanySearch for more papers by this authorW. KIRCH, Corresponding Author W. KIRCH 1st Medical Clinic, Christian Albrechts University, Kiel, GermanyI. Medizinische Klinik, SchittenhelmstraBe 12, D-2300 Kiel, Germany.Search for more papers by this author First published: January 1992 https://doi.org/10.1111/j.1365-2362.1992.tb01929.xCitations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Laurence DR, Bennett PN. Clinical Pharmacology, 6th edn. Edinburgh : Churchill-Livingstone 1987: 612–4. 2 Zimmerman TW, Schenker S. A comparative evaluation of cimetidine and ranitidine. Ration Drug Ther 1985; 19: 1–7. 3 Penston J., Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1986; 1: 192–216. 4 Humphries TJ, Myerson RM, Gilford LM, Aeugle ME, Josie ME, Wood SL, Tannenbaum PJ. A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary. Am J Gastroenterol 1984; 79: 593–6. 5 Davies TG, Pickett DL, Schlosser JH. Evaluation of a worldwide spontaneous reporting system with cimetidine. JAMA 1980; 243: 1912–14. 6 Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Postmarketing surveillance of the safety of cimetidine: twelvemonth morbidity report. Q J Med 1985; 54: 253–68. 7 Eandi M., De Carli GF, Buraglio M., Recchia G. Ranitidine: seven years of drug surveillance. Clin Trials J 1988; 25: 152–7. 8 Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J 1985; 291: 1084–8. 9 Levine JB. Safety profile of Hi-receptor antagonists: current status of famotidine. J Int Med Res 1989; 17(Suppl I): 48A–53A. 10 McGuigan JE. Safety of cimetidine: an overview. Drug Ther 1983;(Suppl): 179–84. 11 Hunt RH. Safety of ranitidine: an overview. Drug Ther 1983;(Suppl): 185–9. 12 Saigenji K., Fukotomi H., Nakazawa S. Famotidine: postmarketing clinical experience. Scand J Gastroenterol 1987; 22(Suppl 134): 34–40. 13 Ginsburg N., Bristow MR, Stinson EB, Harrison DC. Histamine receptors in the human heart. Life Sci 1980; 26: 2245–9. 14 Boyce MJ. Pharmacological characterisation of cardiovascular histamine receptors in man in vivo. Klin Wochenschr 1982; 60: 978–82. 15 Levi R., Chenouda AA, Trzeciakowski JP, Guo ZG, Aaronson LM, Luskind RD, Lee CH. Effects of histamine on the cardiovascular system. Klin Wochenschr 1982; 60: 965–71. 16 Guo ZG, Levi R., Graver LM, Robertson DA, Gay WA. Inotropic effects of histamine in human myocardium: differentiation between positive and negative components. J Cardiovasc Pharmacol 1984; 6: 1210–5. 17 Levi R., Allan G. Histamine-mediated cardiac effects. In: MR Bristow ed. Drug-Induced Heart Disease. Amsterdam : Elsevier-North Holland Biomedical Press 1980: 377–95. 18 Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385–90. 19 Zavecz JH, Levi R. Histamine-induced negative inotropism: mediation by H1 preceptors. J Pharmacol Exp Ther 1978; 206: 274–80. 20 Ziegler A. Kardiovaskuläre Rezeptoren. In: V. Hornbach ed. Kardiovaskulär Wirksame Pharmaka (Kardiologie Band 2). Stuttgart : Schattauer 1988: 21–52. 21 Bailer D., Huchzermeyer H. Histaminwirkungen am Herzen unter Besonderer Berücksichtigung Kardialer Nebenwirkungen von H2-Rezeptor-Antagonisten. Klin Wochenschr 1989; 67: 743–55. 22 Dale HH, Laidlaw PP. The physiological action ofβ-iminazolyl-ethylamine. J Physiol (London) 1910; 41: 318–44. 23 Baumann G., Felix SB, Schrader J., Heidecke CD, Riess G., Erhardt WD, Ludwig L., Loher U., Sebening F., Blömer H. Cardiac contractile and metabolic effects mediated via the myocardial H2-receptor adenylate cyclase system. Characterization of two new specific H2-receptor agonists, impromidine and dimaprit, in the guinea pig and human myocardium. Res Exp Med 1981; 179: 81–98. 24 Bristow MR, Ginsburg R., Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol 1982; 49: 249–51. 25 Eckel L., Gristwood RW, Nawrath H., Owen DA, Satter P. Inotropic and electrophysiological effects of histamine on human ventricular heart muscle. J Physiol (London) 1982; 330: 112–13. 26 Gristwood RW, Owen DA, Eckel L., Satter P., Nawrath H. Response of human ventricular muscle to histamine. J Pharma Pharmacol 1981; 33: 246–7. 27 Baumann G., Felix SB, Riess G., Loher, U., Ludwig L., Blömer H. Effective stimulation of cardiac contractility and myocardial metabolism by impromidine and dimaprit—two new H2-agonistic compounds in the surviving, catecholamine-insensitive myocardium after coronary occlusion. J Cardiovasc Pharmacol 1982; 4: 542–53. 28 Baumann G., Mercader D., Busch U., Felix SB, Loher U., Ludwig L., Sebening H., Heidecke CD, Hagl S., Sebening F., Blömer H. Effects of the H2-receptor agonist impromidine in human myocardium from patients with heart failure due to mitral and aortic valve disease. J Cardiovasc Pharmacol 1983; 5: 618–25. 29 Gristwood RW, Lincoln JCR, Owen DA. Effects of histamine on human isolated heart muscle: comparison with effects of norad-renaline. J Pharma Pharmacol 1980; 32: 145–6. 30 Itskovitz HD. H2-receptor antagonists and the cardiovascular system. Drug Ther 1983;(Suppl): 163–7. 31 Matsuyama K., Hirofumi Y., Okunura K., Matsuyana K., Ogawa H., Morikama Y., Inotsume N., Nakano M. Effects of H1-receptor stimulation on coronary arterial diameter and coronary hemo-dynamics in humans. Circulation 1990; 81: 65–71. 32 Vigorito C., Poto S., Picotti GB, Triggiani M., Marone G. Effect of activation of the H1 receptor on coronary hemodynamics in man. Circulation 1986; 73: 1175–82. 33 Ginsburg R., Bristow MR, Harrison DC, Stinson EB. Studies with isolated human coronary arteries. Some general observations, potential mediators of spasm, role of calcium antagonists. Chest 1980; 78: 180–6. 34 Lorenz W. Histamine release in man. Agents Actions 1975; 5: 402–16. 35 Smith PL, Kagey-Sobotka A., Blecker ER, Traystmann R., Kaplan AP, Gratnick H., Valentine MD, Permutt S., Lichtenstein LM. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66: 1072–80. 36 Baumann G., Loher U., Felix SB, Heidecke CD, Riess G., Ludwig L., Blömer H. Deleterious effects of cimetidine in the presence of histamine on coronary circulation. Possible clinical implications in anaphylactic states in individuals with coronary heart disease. Res Exp Med 1982; 180: 209–13. 37 Bernreiter M. Electrocardiogram of patient in anaphylactic shock. JAMA 1959; 187: 1628. 38 Booth H., Patterson R. Electrocardiographic changes during human anaphylaxis. JAMA 1970; 211: 627. 39 Senges J., Randolf U., Katus H. Ventricular arrhythmias in cardiac anaphylaxis. Naunyn Schmiedebergs Arch Pharmacol 1977; 300: 115–21. 40 Sewing KF. Chemical and biological differences between various H2-receptor antagonists. Scand J Gastroenterol 1988; 23(Suppl (146): 73–7. 41 Milton-Thompson GJ. Comparative clinical pharmacology of the H2-receptor antagonists. Drug Ther 1983;(Suppl): 3–8. 42 Bertaccini G., Coruzzi G. Cholinergic-like effects of the new histamine H2-receptor antagonist ranitidine. Agents Actions 1982; 12: 168–71. 43 Bertaccini G., Coruzzi G. Interaction between histamine H2-receptor antagonists and the cholinergic system. Drug Therapy 1984;(Suppl): 9–14. 44 Hansen WE, Bertl S. Inhibition of cholinesterases by ranitidine. Lancet 1983; i: 235. 45 Bertaccini G., Coruzzi G. Effect of some new histamine H2-receptor antagonists on the guinea-pig papillary muscle. Naunyn Schmiedebergs Arch Pharmacol 1981; 317: 225–7. 46 Bertaccini G., Coruzzi G., Poli E., Adami M. Pharmacology of the novel H2 antagonist famotidine: in vitro studies. Agents Actions 1986; 19: 180–7. 47 Coruzzi G., Poli E., Fesani F., Medici D., Bertaccini G. Negative inotropic effect of some H2-receptor antagonists on the isolated human atria. Experientia 1983; 39: 1284–6. 48 Trzeciakowski JP, Levi R. The cardiac pharmacology of tio-tidine (ICI 125,211): A new histamine H2-receptor antagonists. J Pharmacol Exp Ther 1980; 214: 629–34. 49 Bickel M., Herhling AW, Schoelkens B., Scholtholt B. Chemical and biologic characteristics of roxatidine acetate. Scand J Gastroenterol 1988; 23(Suppl 146): 78–86. 50 Djonlagic H., Mansour A., Hackenjos B., Potratz J. Einfluß der H2-BlockerCimetidin und Ranitidin auf das Erregungsleitungs-system des Herzens. Verh Dtsch Gesellsch Inn Med 1984; 90: 1870–1. 51 Cameron S., Gaide MS, Altman CB, Myerburg RJ, Bassett AL. Cimetidine blocks the adverse electrophysiologic effects of histamine in vitro after myocardial infarction in guinea pigs. Circulation 1983; 68(4/2): 221 (Abstract 884). 52 Dai S. Effects of ranitidine and cimetidine on experimentally induced ventricular arrhythmias in anaesthetized rats. Agents Actions 1986; 17: 460–5. 53 Reding P., Devroede, Barbier P. Bradycardia after cimetidine. Lancet 1977; ii: 1227. 54 Dickey W., Symington M. Broad-complex tachycardia after intravenous cimetidine. Lancet 1978: i: 99–100. 55 Camarri E., Chirone E., Fanteria G., Zocchi M. Ranitidine induced bradycardia. Lancet 1982; i: 160. 56 Shah RR. Symptomatic bradycardia in association with H2:-receptor antagonists. Lancet 1982; ii: 1108. 57 Ishizaki M., Yamada Y., Kido T., Yamaya H., Nogawa K., Matsui S., Marukami E. First-degree atrioventricular block induced by oral cimetidine. Lancet 1987; i: 225–6. 58 Mehta AB, Goldman JM. Cimetidine and cardiac dysrhythmias. Ann Intern Med 1982; 97: 283. 59 Jeffreys DB, Vale JA. Cimetidine and bradycardia. Lancet 1978; i: 828. 60 MacMahon B., Bakshi M., Walsh MJ. Cardiac arrhythmias after intravenous cimetidine. N Engl J Med 1981; 305: 832–3. 61 Cohen J., Weetman AP, Dargie HJ, Krikler DM. Life-threatening arrhythmias and intravenous cimetidine. Br Med J 1979; 2: 768. 62 Lineberger AS, Sprague DH, Battaglini IW. Sinus arrest associated with cimetidine. Anesth Analg 1985; 64: 554–6. 63 Shtimesse B., Daoudal P., Neidhardt A., Ory JP. Bradycardie au cours d'un traitement par cimetidine. Nouv Presse Med 1978; 7: 4233. 64 Karch FE, Becker LA. Bradycardia associated with cimetidine. J Fam Pract 1980; 11: 319–20. 65 Matthews SJ, Michelson PA, Cersosimo RJ. Cimetidine-induced sinus bradycardia. Clin Pharm 1982; 1: 556–8. 66 Nicolic G., Singh JB. Cimetidine, vasopressin and chronotropic incompetence. Med J Aust 1982; 2: 435–6. 67 Tordjman T., Korzets A., Kotas R., Manor J., Klajman A. Complete atrioventricular block and long-term cimetidine therapy. Arch Intern Med 1984; 144: 861. 68 Hiss J., Hepler BR, Falkowski AJ, Sunshine I. Fatal bradycardia after intentional overdose of cimetidine and diazempam. Lancet 1982; ii: 982. 69 Watson AJS, Watson R., Keogh JA. Cimetidine induced arrhythmias. Ir J Med Sci 1892; 151: 348–50. 70 Johnson WS, Miller DR. Ranitidine and bradycardia. Ann Intern Med 1988; 108: 493. 71 Hart AM. Cardiac arrest associated with ranitidine. Br Med J 1989; 299: 519. 72 Tanner LA, Arrowsmith JB. Bradycardia and H2 antagonists. Ann Intern Med 1988; 109: 434. 73 Tryba M., Zevounou F., Wruck G. Stress bleeding and pneumonia in patients under postoperative intensive care receiving ranitidine or pirenzipine. Dtsch Med Wochenschr 1988; 133: 930–6. 74 Engle TR, Luck JC. Histamine2 receptor antagonism by cimetidine and sinus-node function. N Engl J Med 179:301: 591–2. 75 Samuel IO, Dundee JW. Influence of cimetidine on cardiovascular parameters in man. J R Soc Med 1979; 72: 898–901. 76 Barbat J., Warrington SJ. Effects of cimetidine and ranitidine on some non-invasive indices of cardiac function. Br J Pharmacol 1981; 72: 131P. 77 Boyce MJ. Cardiovascular effects of intravenous cimetidine in healthy man. Br J Clin Pharmacol 1981; 12: 268P. 78 Lee PK, Lai CL, Lok ASF, Tse TF, Lai KN, Chow SF, Lam K.C. Br J Clin Pharmacol 1981; 11: 339–43. 79 Jost MV, Wunderlich P., Anderes U., Ritz R. Hypotonie nac i.v. Application von Cimetidin bei kreislauflabilen Patienten. Schweiz Med Wschr 1982; 112: 1012. 80 Tötterman K., Kupari M., Paakkari I., Nieminen MS. Acute cardiovascular effects of intravenous cimetidine. Acta Med Scand 1985; 217: 227–80. 81 Breuer HWM, Hartung HJ, Goeckenjan G., et al. Cimetidin und Ranitidin bei Intensivpatienten. Dtsch Med Wschr 1985; 110: 1151–6. 82 Kiowski W., Frei A. Bolus injection of cimetidine and hypotension in patients in the intensive care unit. Arch Intern Med 1987; 147: 153–6. 83 Goelzer SL, Farin-Rush C., Coursin DB. Ranitidine produces minimal hemodynamic depression in stable intensive care unit patients: a double-blind, prospective study. Crit Care Med 1988; 16: 8–10. 84 Matsukawa S., Hoshi K., Raise A., Sasaki I., Hashimoto Y., Amaha K. The cardiovascular effect of famotidine in intensive care patients. J Intensive Care Med 1986; 106: 73–7. 85 Omote K., Namiki A., Sumita S., Takahashi T., Ujike Y., Hagiwara T. Comparative studies on hemodynamic effects of intravenous cimetidine, ranitidine, and famotidine in intensive care unit patients. Jpn J Anesthesiol 1987; 36: 940–7. 86 Kirch W., Halabi A., Linde M., Santos SR, Ohnhaus EE. Negative effects of famotidine on cardiac performance assessed by non-invasive hemodynamic measurements. Gastroenterology 1989; 96: 1388–92. 87 Hinrichsen H., Halabi A., Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 1990; 48: 302–8. 88 Halabi A., Kirch W. Negative chronotropic effects of nizatidine. Gut 1991; 32: 630–4. Citing Literature Volume22, Issue1January 1992Pages 9-18 ReferencesRelatedInformation